Evidence map›Paper›PMID 41591406›Full record

ArticleJournal of medicinal chemistry2026

Optimizing the Antibiotic Potency and Metabolic Stability of Pyridomycin Using a Semisynthetic Approach.

Katherine Valderrama, Oliver Horlacher, Gabriel Publicola, Patrick Eisenring, Maryline Kienle, Samira Boarbi, Mehdi Kiass, Jana Korduláková, Jonathan Chatagnon, Catherine Piveteau and 12 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Katherine ValderramaUniv. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France.
Oliver HorlacherDepartment of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zürich, 8093 Zurich, Switzerland.
Gabriel PublicolaUniv. Toulouse, CNRS, IPBS, 31077 Toulouse, France.
Patrick EisenringDepartment of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zürich, 8093 Zurich, Switzerland.
Maryline KienleDepartment of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zürich, 8093 Zurich, Switzerland.
Samira BoarbiUnit "Tuberculosis & Mycobacteria", Human Bacterial Diseases Service, Infectious Diseases in Humans, 1050 Brussels, Belgium.
Mehdi KiassUnit "Tuberculosis & Mycobacteria", Human Bacterial Diseases Service, Infectious Diseases in Humans, 1050 Brussels, Belgium.
Jana KordulákováFaculty of Natural Sciences, Department of Biochemistry, Comenius University in Bratislava, Ilkovičova 6, Mlynská dolina, 842 15 Bratislava, Slovakia.
Jonathan ChatagnonUniv. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France.
Catherine PiveteauUniv. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000 Lille, France.
Florence LerouxUniv. Lille, Inserm, Institut Pasteur de Lille, U1177 - Drugs and Molecules for Living Systems, F-59000 Lille, France.
Karin SavkováFaculty of Natural Sciences, Department of Biochemistry, Comenius University in Bratislava, Ilkovičova 6, Mlynská dolina, 842 15 Bratislava, Slovakia.
Monika ZáhorszkáFaculty of Natural Sciences, Department of Biochemistry, Comenius University in Bratislava, Ilkovičova 6, Mlynská dolina, 842 15 Bratislava, Slovakia.
Francois-Xavier CantrelleCNRS, EMR9002 BSI Integrative Structural Biology, 59000 Lille, France.ORCID 0000-0002-3413-5443
Christian LherbetSynthèse et Physico-Chimie de Molécules d'Intérêt Biologique (LSPCMIB), UMR 5068, CNRS, Université Toulouse (UT), 31062 Toulouse, France.
Lionel MoureyUniv. Toulouse, CNRS, IPBS, 31077 Toulouse, France.ORCID 0000-0002-8259-1259
Katarína MikušováFaculty of Natural Sciences, Department of Biochemistry, Comenius University in Bratislava, Ilkovičova 6, Mlynská dolina, 842 15 Bratislava, Slovakia.ORCID 0000-0002-0100-4877
Vanessa MathysUnit "Tuberculosis & Mycobacteria", Human Bacterial Diseases Service, Infectious Diseases in Humans, 1050 Brussels, Belgium.
Reiner AichholzPK Sciences, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland.
Laurent MaveyraudUniv. Toulouse, CNRS, IPBS, 31077 Toulouse, France.ORCID 0000-0003-4610-8319
Karl-Heinz AltmannDepartment of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zürich, 8093 Zurich, Switzerland.ORCID 0000-0002-0747-9734
Ruben C HartkoornUniv. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur Lille, U1019 - UMR 9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France.ORCID 0000-0001-7315-1553

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pyridomycin is a natural product with potent activity against

Indexed as

Antitubercular AgentsTuberculosis, PulmonaryAnimalsAnti-Bacterial AgentsHumansMiceMicrobial Sensitivity TestsOligopeptidesAnti-Bacterial AgentsAntitubercular AgentsOligopeptidespyridomycin

Identifiers

PMID41591406
PMCPMC12910649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.